The stock quoted a 52-week high price of Rs 1063.75 and a low of Rs 584.2. The return on equity for the stock stood at 24.32 per cent. About 24,433 shares have changed hands on the counter so far.
The stock’s beta value, which measures its volatility in relation to the broader market, stood at 1.06.
The scrip has been an underperformer, down 26.96 per cent in the past one year in comparison with a 17.8 per cent gain in Sensex.
On the technical charts, the 200-day moving average (DMA) of the stock stood at Rs 584.2 on April 19, while the 50-DMA was at Rs 663.62. If a stock trades well above 50-DMA and 200-DMA, it usually means the immediate trend is upward. On the other hand, if the stock trades well below 50-DMA and 200-DMA both, it is considered a bearish trend and if trades between these averages, then it suggests the stock can go either way.
Promoters held 48.76 per cent stake in Aurobindo Pharma Ltd. as of 31-Mar-2022. Mutual funds and foreign institutional investors held 10.09 per cent and 20.83 per cent stake.